Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire
ICOMPRE 2 DE CADA CAJA puma biotechnology inc Y OBTENGA UN 70% DE DESCUENTO!
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib - Pharmaceutical Business review
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+
Puma Biotechnology, Inc. 2020 Current Report 8-K
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Biotechnology
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology
Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug - TheStreet
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
In the wake of Puma Biotechnology, Inc.'s (NASDAQ:PBYI) latest US$17m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St News
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results | Business Wire
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
puma pharmaceuticals stock price Off 54% - canerofset.com
Puma Biotechnology
Puma Shares Soar 81% Over 2 Days | Los Angeles Business Journal
Puma catches fifth approval, hunts new indication for Nerlynx
Puma Biotechnology shares rocket after biopharma zips past Street's 4Q estimate
PBYI Institutional Ownership - Puma Biotechnology Inc Stock
Former Puma Biotechnology exec is accused of making $1.2 million from insider trading - Los Angeles Times
